NFKB1 and psoriatic arthritis: Anti-IL-17 monoclonal antibodies that prevent IL-17 receptor binding and downstream JAK/STAT and NFkB signaling. Currently, FDA-approved for ankylosing spondylitis and psoriatic arthritis treatment.